The Association of Fatty Liver and Diabetes Risk.

Okamoto, Masako; Takeda, Yasuhisa; Yoda, Yoshioki; Kobayashi, Kazuhisa; Fujino, Masayuki; Yamagata, Zentaro

doi:10.2188/jea.13.15

Cited by 49 publications

(46 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two longitudinal studies in Asian populations using ultrasound (US)-diagnosed NAFLD have demonstrated that NAFLD is a risk factor for the development of type 2 diabetes in Koreans [7] and Japanese men [8]. In contrast, a study in a Japanese cohort that included women [9] failed to show this relationship. Hence, the emergence of NAFLD prior to the development of frank diabetes is not well studied in women.…”

Section: Introductionmentioning

confidence: 99%

Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes

et al. 2010

View full text Add to dashboard Cite

Aims/hypothesis Non-alcoholic fatty liver disease (NAFLD) is common in type 2 diabetes but it is unknown whether NAFLD is prevalent in European women at risk of type 2 diabetes. We studied the prevalence of, and risk factors for, NAFLD in European women with previous gestational diabetes (GDM) at high risk of type 2 diabetes. Methods A total of 110 women with previous GDM and 113 without previous GDM, with non-diabetic glucose tolerance were recruited retrospectively from antenatal databases. Participants underwent liver ultrasound scan examination, anthropometry and blood sampling for liver function tests and to determine levels of fasting lipids, NEFA and insulin and glucose concentrations in order to derive insulin sensitivity and insulin secretion indices (HOMA%S and HOMA%B, respectively). Results There was no significant difference in BMI in women with previous GDM compared with those without previous GDM (28.9±0.6 vs. 27.9±0.6 kg/m 2 , respectively; p=0.12). Women with previous GDM had higher fasting and 2 h glucose concentrations following a 75 g OGTT ([mean ± SEM] fasting glucose 5.3±0.1 vs. 5.1±0.1 mmol/l, p=0.02; 2 h glucose 6.8±0.2 vs. 5.8±0.3 mmol/l, p=0.02), dyslipidaemia (LDL-cholesterol 3.3±0.1 vs. 2.8±0.1 mmol/l; HDLcholesterol [median {interquartile range}] 1.3 [1.2-1.6] vs. 1.8 [1.5-1.9] mmol/l; triacylglycerol 1.3 [0.9-1.6] vs. 1.0 [0.7-1.7] mmol/l, all p≤0.03), higher insulin secretion and lower insulin sensitivity. NAFLD prevalence was greater in women with previous GDM compared with those without previous GDM: 38% (95% CI 28-47%) vs. 17% (95% CI 10-24%), p=0.001. In multiple logistic regression analysis, lower insulin sensitivity and raised serum alanine transaminase concentrations were associated with NAFLD. Conclusions/interpretation NAFLD is prevalent in European women with previous GDM. Impaired insulin sensitivity and increased liver transaminase activity are closely associated with NAFLD in these women.

show abstract

Section: Introductionmentioning

confidence: 99%

Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes

et al. 2010

View full text Add to dashboard Cite

show abstract

“…There are now about 20 observational studies that have assessed the association between NAFLD and the risk of new-onset type 2 diabetes [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25].…”

Section: Epidemiological Evidence Linking Nafld To the Risk Of New-onmentioning

confidence: 99%

“…Amongst these published studies, nearly all (except for the study by Okamoto et al [9]) have shown that NAFLD was associated with a substantially increased risk of new-onset type 2 diabetes. The risk of diabetes among these published studies varied markedly from a 33% increase [14] to a 5.5 fold increase in risk [11].…”

Section: Epidemiological Evidence Linking Nafld To the Risk Of New-onmentioning

confidence: 99%

“…Collectively, although there is now convincing evidence that NAFLD is associated with an increased risk of new-onset type 2 diabetes [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25], and there is emerging evidence that this risk varies according to the severity of NAFLD (as detected either by ultrasonography or by use of non-invasive fibrosis scoring systems) [9,[12][13][14], further evidence is unquestionably needed in non-Asian populations, as nearly all of the studies summarised in Table 1 have been conducted in various Asian populations, and most of the evidence obtained to date has been obtained in South Korean individuals. However, a recent analysis from the Multi-Ethnic Study of Atherosclerosis study involving more than 3,000 United States nondiabetic individuals has confirmed that NAFLD as detected by computed tomography was independently associated with a two-fold increased risk of developing type 2 diabetes [25].…”

Section: Epidemiological Evidence Linking Nafld To the Risk Of New-onmentioning

confidence: 99%

See 1 more Smart Citation

Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?

Targher

Marchesini

Byrne

2016

Diabetes & Metabolism

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liverrelated mortality and morbidity. Over the last 10 years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action and secretion. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 2 AbstractNonalcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10 years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action and secretion. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes.

show abstract

“…REVIEW 340 | Сахарный диабет / Diabetes Mellitus талось, что они являются просто структурными клеточны-ми компонентами, однако в настоящее время появились данные о том, что избыток мембранных церамидов может способствовать развитию ИР [27] ввиду того, что церами-ды имеют функцию клеточного сигналинга, потенциально обеспечивая механизм связи печеночного метаболизма липидов и печеночного воспаления. Не так давно пред-полагалось, что изменения в метаболизме церамидов мо-гут также объяснять, почему НАЖБП с ИР ассоциирована с другими характерными признаками метаболического синдрома, в то время как генотип пататин-подобного доме-на, содержащего протеин 3 фосфолипазу (PNPLA3 148MM), ассоциированный с НАЖБП, не связан с метаболическим синдромом (и не связан с повышенным риском развития СД2) [28]. В данном исследовании оценивался печеноч-ный липидом на основании 125 биопсий, пациенты были разделены по двум признакам: ИР (оценка проводилась по уровню HOMA) и генотипу PNPLA3 (PNPLA3 148MM/MI и PNPLA3 148II).…”

Section: инсулинорезистентность и нажбпunclassified

Nonalcoholic fatty liver disease: cause or consequence of insulin resistance?

Mishina¹,

Mayorov²,

Богомолов³

et al. 2017

Diabetes mellitus

View full text Add to dashboard Cite

Более 30 лет назад Ludwig J. (1980) описал заболева-ние, сходное с алкогольным стеатогепатитом, у пациентов с сахарным диабетом (СД), не употребляющих алкоголь, и назвал данное заболевание неалкогольным стеатогепа-титом (НАСГ) [1]. Неалкогольная жировая болезнь печени (НАЖБП) является самым распространенным хроническим заболеванием печени и приняла масштаб эпидемии, так же как ожирение и СД 2 типа (СД2) [2]. НАЖБП включает в себя спектр заболеваний от жирового гепатоза без признаков воспаления до НАСГ, цирроза печени и гепатоцеллюляр-ной карциномы [3]. ЭПИДЕМИОЛОГИЯОписанная распространенность НАЖБП широ-ко варьирует в зависимости от изучаемой популяции и от используе мого метода диагностики. Распространен-ность гистологически подтвержденной НАЖБП состав-ляет от 20 до 51%, однако, по данным ультразвукового метода исследования, НАЖБП встречается реже, от 17 до 46% [4] Неалкогольная жировая болезнь печени (НАЖБП) и сахарный диабет 2 типа (СД2) -патологические состояния, ассоцииро-ванные друг с другом и достигающие размеров эпидемии. Одним из наиболее значимых факторов риска развития как СД2, так и НАЖБП является ожирение, которое усиливает имеющуюся инсулинорезистентность (ИР). Последняя является ос-новным патогенетическим звеном СД2 и НАЖБП, связывая эти два патологических состояния. В настоящее время повышен интерес к поиску неинвазивных методик исследования; для оценки фиброза и определения показаний для биопсии печени неинвазивным методом используется Шкала оценки стадии фиброза при НАЖБП (NAFLD fibrosis score), расширенная панель фиброза печени (ELF) и транзиентная эластография. Однако золотым стандартом диагностики остается биопсия печени. Ввиду того, что у пациентов с СД чаще выявляется НАЖБП, чем в общей популяции, а также учитывая, что наличие СД явля-ется фактором риска прогрессии НАЖБП, данная когорта пациентов должна находиться под более тщательным контролем клиницистов. Данная обзорная работа посвящена поиску причинно-следственных связей таких коморбидных заболеваний, как НАЖБП и различные нарушения углеводного обмена, а также приоритетным направлениям диагностики НАЖБП.КЛЮЧЕВЫЕ СЛОВА: инсулинорезистентность; сахарный диабет; неалкогольная жировая болезнь печени; неалкогольный стеатогепатит; ожирение NONALCOHOLIC FATTY LIVER DISEASE: CAUSE OR CONSEQUENCE OF INSULIN RESISTANCE?© Ekaterina E. Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are pathological conditions that are co-occurring, and have been reaching epidemic proportions. One of the most significant risk factors for the development of both T2DM and NAFLD is obesity, which increases existing insulin resistance (IR). IR thought to be one of the main pathogenic causes linking T2DM and NAFLD. In recent years, there has been increased interest in obtaining non-invasive methods for assessing fibrosis and determining indications for liver biopsy, such as the NAFLD fibrosis score, extended liver fibrosis panel, and transient elastography. However, liver biopsy remains the gold standard for diagnosing NAFLD. Given that pa...

show abstract

The Association of Fatty Liver and Diabetes Risk.

Cited by 49 publications

References 25 publications

Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes

Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes

Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?

Nonalcoholic fatty liver disease: cause or consequence of insulin resistance?

Contact Info

Product

Resources

About